ArticleBiomaterials research2025
Tryptamine-Functionalized Lipid Nanocarriers Co-delivering SMO/BRD4 Inhibitors for Synergistic Medulloblastoma Therapy.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of medulloblastoma (MB) remains a significant challenge, primarily attributed to the presence of cancer stem cells and the inadequate delivery of therapeutic agents across the blood-brain barrier. GLI, as a regulator of the hedgehog signaling pathway in normal cerebellum development, also exerts pivotal functions in MB initiation, progression, and metastasis and maintains the stemness of MB stem cells. In this study, we devised a combined therapeutic approach by integrating the BRD4 inhibitor JQ1 with the SMO inhibitor saikosaponin B1 (SSB1) to inhibit MB via regulation of GLI activation. The results suggested that JQ1 and SSB1 synergistically inhibited MB proliferation, constricted MB metastasis, and down-regulated stem cell phenotypes via reduced GLI and MYC expression. Tryptamine-derived lipid nanoparticles (NPs) transported JQ1 and SSB1 to MB tissues. The targeted NPs demonstrated prolonged drug release kinetics and significantly improved their accumulation in MB tumors. Systemic administration of drug-loaded targeted NPs significantly decreased tumor burden without hepatic toxicity in xenograft MB-bearing mice. The combination of JQ1 and SSB1 presents an innovative therapeutic paradigm for suppressing MB proliferation, recurrence, and metastasis, with the potential to drive the development of novel MB treatment strategies in the future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.